162 related articles for article (PubMed ID: 23053896)
1. Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.
Mokrowiecka A; Zonnur S; Veits L; Musial J; Kordek R; Lochowski M; Kozak J; Malecka-Panas E; Vieth M; Hartmann A
Dig Dis Sci; 2013 Mar; 58(3):699-705. PubMed ID: 23053896
[TBL] [Abstract][Full Text] [Related]
2. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma.
Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L
Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732
[TBL] [Abstract][Full Text] [Related]
3. Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.
Weimann A; Rieger A; Zimmermann M; Gross M; Hoffmann P; Slevogt H; Morawietz L
Virchows Arch; 2010 Nov; 457(5):537-45. PubMed ID: 20844891
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis.
Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M
J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
6. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
7. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
8. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation.
Bailey T; Biddlestone L; Shepherd N; Barr H; Warner P; Jankowski J
Am J Pathol; 1998 Jan; 152(1):135-44. PubMed ID: 9422531
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
10. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
[TBL] [Abstract][Full Text] [Related]
11. Mucin expression and proliferating cell index of esophageal Barrett's adenocarcinoma.
Yamamoto S; Kijima H; Hara T; Chino O; Shimada H; Tanaka M; Inokuchi S; Makuuchi H
Int J Mol Med; 2005 Sep; 16(3):375-80. PubMed ID: 16077942
[TBL] [Abstract][Full Text] [Related]
12. Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype.
van der Woude CJ; Jansen PL; Tiebosch AT; Beuving A; Homan M; Kleibeuker JH; Moshage H
Hum Pathol; 2002 Jul; 33(7):686-92. PubMed ID: 12196918
[TBL] [Abstract][Full Text] [Related]
13. Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study.
Mendes de Almeida JC; Chaves P; Pereira AD; Altorki NK
Ann Surg; 1997 Dec; 226(6):725-33; discussion 733-5. PubMed ID: 9409571
[TBL] [Abstract][Full Text] [Related]
14. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
15. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.
Phillips RW; Frierson HF; Moskaluk CA
Am J Surg Pathol; 2003 Nov; 27(11):1442-7. PubMed ID: 14576477
[TBL] [Abstract][Full Text] [Related]
16. Does Cytokeratin7/20 immunoreactivity help to distinguish Barrett's esophagus from gastric intestinal metaplasia? Results of a prospective study of 75 patients.
Schilling D; Spiethoff A; Rosenbaum A; Hartmann D; Eickhoff A; Jakobs R; Weickert U; Rebe M; Bohrer MH; Riemann JF
Pathol Res Pract; 2005; 200(11-12):801-5. PubMed ID: 15792123
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor expression in the mucosal tissue at the gastroesophageal junction.
Trowbridge R; Mittal SK; Sharma P; Hunter WJ; Agrawal DK
Exp Mol Pathol; 2012 Oct; 93(2):246-9. PubMed ID: 22664272
[TBL] [Abstract][Full Text] [Related]
18. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas.
Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG
Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological study of early adenocarcinoma of the gastric cardia: comparison with early adenocarcinoma of the distal stomach and esophagus.
Tajima Y; Nakanishi Y; Yoshino T; Kokawa A; Kusano M; Shimoda T
Oncology; 2001; 61(1):1-9. PubMed ID: 11474241
[TBL] [Abstract][Full Text] [Related]
20. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
